Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Sulfasalazine

FDA-approved product (tablet, oral), marketed as Azulfidine, Azulfidine En-Tabs, S.a.s.-500 and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Sulfasalazine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Juvenile idiopathic arthritis
  • Rheumatoid arthritis
  • Ulcerative colitis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Aminosalicylic acid and similar agents
FDA pharmacologic class
Aminosalicylate FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA32.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli20.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae13.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis60.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Sulfasalazine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Sulfasalazine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Enbrel-Sulfasalazin-Early-Axial Spondyloarthritis (AS)

    NCT00844142 · start 2005-11

    Registered record
    Registry ID
    NCT00844142
    Conditions
    Moderate to Severe Active Axial Spondyloarthritis
    Interventions
    Etanercept 25mg; Sulfasalazine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2005-11
    Completion
    2013-07
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionModerate to Severe Active Axial Spondyloarthritis
    InterventionEtanercept 25mg; Sulfasalazine
    PhasePhase 2
    Registry statusUnknown

  • Treatment of Early Aggressive Rheumatoid Arthritis (TEAR)

    NCT00259610 · start 2004-05

    Registered record
    Registry ID
    NCT00259610
    Conditions
    Rheumatoid Arthritis
    Interventions
    methotrexate; sulfasalazine; hydroxychloroquine; etanercept
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-05
    Completion
    2009-06
    Enrolment
    755

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis
    Interventionmethotrexate; sulfasalazine; hydroxychloroquine; etanercept
    PhasePhase 4
    Registry statusCompleted

  • Sulfasalazine and Endothelial Function

    NCT00554203 · start 2003-07

    Registered record
    Registry ID
    NCT00554203
    Conditions
    Coronary Artery Disease
    Interventions
    Sulfasalazine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2003-07
    Completion
    2007-12
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease
    InterventionSulfasalazine
    PhaseNot applicable
    Registry statusCompleted

  • Aggressive Combination Drug Therapy in Very Early Polyarticular Juvenile Idiopathic Arthritis

    NCT01015547 · start 2003-05

    Registered record
    Registry ID
    NCT01015547
    Conditions
    Juvenile Idiopathic Arthritis
    Interventions
    Infliximab plus methotrexate; Combination of DMARDs; Methotrexate alone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-05
    Completion
    2013-12
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionJuvenile Idiopathic Arthritis
    InterventionInfliximab plus methotrexate; Combination of DMARDs; Methotrexate alone
    PhasePhase 3
    Registry statusCompleted

  • Triple III Comparison of Leflunomide Alone Versus Two DMARD Combinations in the Treatment of Rheumatoid Arthritis

    NCT00579878 · start 2001-03-27

    Registered record
    Registry ID
    NCT00579878
    Conditions
    Rheumatoid Arthritis
    Interventions
    Leflunomide; Methotrexate-Sulfasalazine-Hydroxychloroquine; Leflunomide-Sulfasalazine-Hydroxychloroquine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-03-27
    Completion
    2010-03-11
    Enrolment
    69

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis
    InterventionLeflunomide; Methotrexate-Sulfasalazine-Hydroxychloroquine; Leflunomide-Sulfasalazine-Hydroxychloroquine
    PhasePhase 3
    Registry statusCompleted